Vivani Medical Inc (VANI)
1.28
+0.05
(+3.67%)
USD |
NASDAQ |
Jun 25, 16:00
1.30
+0.02
(+1.56%)
Pre-Market: 08:18
Vivani Medical Enterprise Value: 40.72M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 40.72M |
| June 24, 2024 | 38.23M |
| June 21, 2024 | 39.08M |
| June 20, 2024 | 39.08M |
| June 18, 2024 | 43.47M |
| June 17, 2024 | 48.97M |
| June 14, 2024 | 58.32M |
| June 13, 2024 | 59.42M |
| June 12, 2024 | 59.97M |
| June 11, 2024 | 59.97M |
| June 10, 2024 | 60.52M |
| June 07, 2024 | 59.14M |
| June 06, 2024 | 58.87M |
| June 05, 2024 | 61.07M |
| June 04, 2024 | 60.52M |
| June 03, 2024 | 62.17M |
| May 31, 2024 | 59.97M |
| May 30, 2024 | 60.52M |
| May 29, 2024 | 60.52M |
| May 28, 2024 | 61.62M |
| May 24, 2024 | 62.17M |
| May 23, 2024 | 59.97M |
| May 22, 2024 | 67.11M |
| May 21, 2024 | 68.49M |
| May 20, 2024 | 71.51M |
| Date | Value |
|---|---|
| May 17, 2024 | 80.03M |
| May 16, 2024 | 78.66M |
| May 15, 2024 | 75.36M |
| May 14, 2024 | 70.96M |
| May 13, 2024 | 72.06M |
| May 10, 2024 | 69.86M |
| May 09, 2024 | 64.92M |
| May 08, 2024 | 63.82M |
| May 07, 2024 | 65.46M |
| May 06, 2024 | 68.76M |
| May 03, 2024 | 68.21M |
| May 02, 2024 | 64.92M |
| May 01, 2024 | 61.62M |
| April 30, 2024 | 59.42M |
| April 29, 2024 | 59.97M |
| April 26, 2024 | 59.97M |
| April 25, 2024 | 63.54M |
| April 24, 2024 | 65.46M |
| April 23, 2024 | 69.31M |
| April 22, 2024 | 62.17M |
| April 19, 2024 | 63.82M |
| April 18, 2024 | 69.59M |
| April 17, 2024 | 71.51M |
| April 16, 2024 | 75.91M |
| April 15, 2024 | 81.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.574M
Minimum
Dec 30 2022
203.03M
Maximum
Aug 31 2022
38.85M
Average
29.78M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 61.31M |
| AIM ImmunoTech Inc | 11.80M |
| IGC Pharma Inc | 31.39M |
| NovaBay Pharmaceuticals Inc | 2.939M |
| Protalix BioTherapeutics Inc | 66.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.039M |
| Total Expenses (Quarterly) | 6.227M |
| EPS Diluted (Quarterly) | -0.12 |
| Earnings Yield | -38.28% |